Dopamine/serotonin receptor ligands. Part 17: A cross-target SAR approach: Affinities of azecine-styled ligands for 5-HT2A versus D1 and D2 receptors

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 13, 2008, Pages 3809-3813

  Enzensperger, Christoph ^a   Görnemann, Tilo ^b   Pertz, Heinz H ^b   Lehmann, Jochen ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Azecine; Cross target SAR; Dopamine; Protein ligand interaction; Receptor ligand; Serotonin

Indexed keywords

AZECINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; KETANSERIN; LIGAND; SEROTONIN 2A RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CORONARY ARTERY; DRUG BINDING; DRUG STRUCTURE; NONHUMAN; STRUCTURE ACTIVITY RELATION; SWINE;

AMINO ACIDS; ANIMALS; CORONARY VESSELS; DOPAMINE; DOPAMINE ANTAGONISTS; HUMANS; HYDROGEN-ION CONCENTRATION; LIGANDS; PROTEIN BINDING; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; SEROTONIN; STRUCTURE-ACTIVITY RELATIONSHIP; SWINE;

SUS;

EID: 44849121342     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.04.081     Document Type: Article

References (20)

1. Enzensperger C., Müller F.K., Schmalwasser B., Wiecha P., Traber H., and Lehmann J. J. Med. Chem. 50 (2007) 4528
2. Roth B.L., Sheffler D.J., and Kroeze W.K. Nat. Rev. Drug Discov. 3 (2004) 353
3. Meltzer H.Y. Curr. Opin. Pharmacol. 4 (2004) 53
4. Horacek J., Bubenikova-Valesova V., Kopecek M., Palenicek T., Dockery C., Mohr P., and Hoschl C. CNS Drugs 20 (2006) 389
5. Hopkins A.L., Mason J.S., and Overington J.P. Curr. Opin. Struct. Biol. 16 (2006) 127
6. Hoefgen B., Decker M., Mohr P., Schramm A.M., Rostom S.A., El Subbagh H., Schweikert P.M., Rudolf D.R., Kassack M.U., and Lehmann J. J. Med. Chem. 49 (2006) 760
7. Hamacher A., Weigt M., Wiese M., Hoefgen B., Lehmann J., and Kassack M.U. BMC Pharmacol. 6 (2006) 11
8. El Subbagh H., Wittig T., Decker M., Elz S., Nieger M., and Lehmann J. Arch. Pharm. (Weinheim) 335 (2002) 443
9. Rostom, S. A.; Farghaly, A. M.; Soliman, F. S.; el Semary, M. M.; Elz, S.; Lehmann, J. LE 300. Arch. Pharm. (Weinheim) 2001, 334, 241.
10. Mohr P., Decker M., Enzensperger C., and Lehmann J. J. Med. Chem. 49 (2006) 2110
11. Enzensperger C., and Lehmann J. J. Med. Chem. 49 (2006) 6408
12. Enzensperger C., Kilian S., Ackermann M., Koch A., Kelch K., and Lehmann J. Bioorg. Med. Chem. Lett. 17 (2007) 1399
13. Cushing D.J., and Cohen M.L. J. Pharmacol. Exp. Ther. 264 (1993) 193
14. Klabunde T. Br. J. Pharmacol. 152 (2007) 5
15. Joost P., and Methner A. Genome Biol. 3 (2002) 1
16. Surgand J.S., Rodrigo J., Kellenberger E., and Rognan D. Proteins 62 (2006) 509
17. Strader C.D., Sigal I.S., and Dixon R.A. Trends Pharmacol. Sci. Suppl (1989) 26
18. Andersen P.H., Gronvald F.C., Hohlweg R., Hansen L.B., Guddal E., Braestrup C., and Nielsen E.B. Eur. J. Pharmacol. 219 (1992) 45
19. Wu W.L., Burnett D.A., Spring R., Greenlee W.J., Smith M., Favreau L., Fawzi A., Zhang H., and Lachowicz J.E. J. Med. Chem. 48 (2005) 680
20. Neumeyer J.L., Kula N.S., Bergman J., and Baldessarini R.J. Eur. J. Pharmacol. 474 (2003) 137